About IGM Biosciences
IGM Biosciences is a company based in Mountain View (United States) founded in 2010 was acquired by Concentra Biosciences in July 2025. IGM Biosciences has raised $102.67 million across 3 funding rounds from investors including Haldor Topsoe, Janus Henderson Investors and Redmile Group. The company has 181 employees as of December 31, 2022. IGM Biosciences offers products and services including IgM Antibodies and Antibody Platform. IGM Biosciences operates in a competitive market with competitors including Moderna, Horizon Therapeutics, Forge Biologics, Dren Bio and argenx, among others.
- Headquarter Mountain View, United States
- Employees 181 as on 31 Dec, 2022
- Stage Public
-
Sectors
Healthcare
-
Email
Locked
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Igm Biosciences, Inc.
-
Annual Revenue
Not available
-
Net Profit
-$195.8 M (USD)21as on Dec 31, 2024
-
EBITDA
-$208.58 M (USD)21as on Dec 31, 2024
-
Total Equity Funding
$102.67 M (USD)
in 3 rounds
-
Latest Funding Round
$120 M (USD), Post-IPO
Jul 03, 2023
-
Investors
Haldor Topsoe
& 4 more
-
Employee Count
181
as on Dec 31, 2022
-
Acquired by
Concentra Biosciences
(Jul 01, 2025)
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of IGM Biosciences
IGM Biosciences offers a comprehensive portfolio of products and services, including IgM Antibodies and Antibody Platform.
Engineered for targeting autoimmune and inflammatory diseases effectively.
Platform for developing IgM-based therapeutics for disease treatment.
People of IGM Biosciences
Unlock access to complete
Funding Insights of IGM Biosciences
IGM Biosciences has successfully raised a total of $102.67M across 3 strategic funding rounds. The most recent funding activity was a Post-IPO round of $120 million completed in July 2023. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in IGM Biosciences
IGM Biosciences has secured backing from 5 investors, including institutional and venture fund investors. Prominent investors backing the company include Haldor Topsoe, Janus Henderson Investors and Redmile Group.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Multiple sectors are targeted for venture capital investments.
|
Locked | Locked | Locked | |
|
Venture capital and private equity firm
|
Locked | Locked | Locked | |
|
Operates as an employee-owned hedge fund focused on long/short equity strategies.
|
Locked | Locked | Locked |
Investor details for IGM Biosciences
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by IGM Biosciences
Investment portfolio details for IGM Biosciences
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - IGM Biosciences
Detailed financials for IGM Biosciences
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Igm Biosciences Comparisons
Peer comparison for IGM Biosciences
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of IGM Biosciences
IGM Biosciences operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Moderna, Horizon Therapeutics, Forge Biologics, Dren Bio and argenx, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
mRNA-based therapeutics for diseases including cancer and infections are developed.
|
|
| Locked | Locked | Locked |
Developer of drugs for treating rare and autoimmune diseases
|
|
| Locked | Locked | Locked |
Gene therapies for rare diseases are developed to treat patients.
|
|
| Locked | Locked | Locked |
Therapeutic antibodies are developed for cancer, autoimmune, and serious diseases.
|
|
| Locked | Locked | Locked |
Antibody-based drugs are developed for autoimmune diseases and cancer treatment.
|
|
| Locked | Locked | Locked |
Developer of antibodies to treat complement-mediated neurodegenerative diseases
|
Detailed competitors of IGM Biosciences
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Igm Biosciences
Complete news archive for IGM Biosciences
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about IGM Biosciences
IGM Biosciences was founded in 2010 and raised its 1st funding round 1 year after it was founded.
IGM Biosciences is headquartered in Mountain View, United States. It is registered at Mountain View, California, United States.
Fred M Schwarzer is the current CEO of IGM Biosciences.
IGM Biosciences is a funded company, having raised a total of $102.67M across 3 funding rounds to date.
As of Dec 31, 2022, the latest employee count at IGM Biosciences is 181.
IGM Biosciences was founded in 2010 in Mountain View, United States, within the biotechnology sector. Focus is placed on developing IgM and IgA antibodies that target CD20, PD-L1, CTLA-4, and death receptor 5. These antibodies are advanced for treating Non-Hodgkins lymphoma, solid tumors, HIV, and HBV. Operations emphasize immune checkpoint modulation and infectious disease control through clinical-stage programs.
IGM Biosciences's top competitors include Moderna, argenx and Forge Biologics.
IGM Biosciences offers IgM Antibodies and Antibody Platform.
IGM Biosciences has 5 investors. Key investors include Haldor Topsoe, Janus Henderson Investors, Redmile Group, Vivo Capital, and Concentra Biosciences.